Hatiboglu G, et al. - Using a single-center cohort of the multicenter Phase I (n = 14/30 at 3 sites) and Pivotal (n = 15/115 at 13 sites) trials of Transurethral Ultrasound Ablation (TULSA) including men with localized prostate cancer, researchers assessed how safety, functional outcomes, and PSA following MR (magnetic resonance imaging)-Guided TULSA of prostatic tissue were influenced by intensified treatment parameters. For participants, baseline and 6-month follow-up data were analyzed. In Phase I trial, acceptable clinical safety of TULSA was evident. Without influencing 6-month adverse events or functional outcomes, an increase in ablation coverage from 90 to 98% of the prostate was achieved with intensified treatment parameters in the TULSA-PRO Ablation Clinical Trial. To assess oncological safety, long-term follow-up and 12-month biopsies are required.